In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ian Schofield

Edinburgh, U.K
Ian Schofield has been writing on issues affecting the pharmaceutical and biotech industry since the mid-1980s, specialising in EU and global policy and regulatory affairs.  As well as writing, editing and commissioning articles for Pharma Intelligence, Ian works for the Ask the Analyst service, providing tailor-made answers to questions posed directly by clients. He has a degree in modern languages from the University of Bath. Outside the realm of work, Ian plays guitar in a traditional music group and also enjoys a touch of cycling and gardening. He lives by the seaside about three miles from the centre of Edinburgh.
Advertisement
Set Alert for Articles By Ian Schofield

Latest From Ian Schofield

UK’s No-Deal Brexit Plans For SPC Waiver Could Reduce IP Rights, Warns BIA

The UK’s plans to amend the supplementary protection certificate waiver legislation in the event of a no-deal Brexit could lead to the curtailment of IP protections, not only the terms of SPCs but regulatory data protection and orphan exclusivity too, the BIA claims.
United Kingdom Intellectual Property

NICE Says Initial No To Epidyolex In England, But GW Pharma Remains Upbeat

Draft guidance from NICE has recommended against the use of GW Pharmaceuticals’ Epidyolex for refractory epilepsy, but the company believes it has the data needed to ensure a positive outcome to the appraisal.
United Kingdom Health Technology Assessment

UK Govt Asks: Are Trial Sponsors Ready For No-Deal Brexit?

Pharma firms are being asked to let the government know how prepared they are in terms of ensuring supplies of investigational medicines and other clinical trial supplies in the event of a no-deal Brexit at the end of October.

United Kingdom Brexit

Will Pharma Firms Bear Cost Of UK Govt’s Latest No-Deal Brexit Supply Plans?

Life science companies are uneasy over the government’s latest proposals for emergency medical supplies to the UK if the country leaves the EU without a deal.

United Kingdom Trade

Italy Unveils New Payment Model For Novartis’s CAR-T Kymriah

The Italian authorities have agreed a new kind of reimbursement model for Novartis's CAR-T therapy Kymriah that involves payment in instalments depending on the patient’s response to treatment.

Italy Reimbursement

NHS England Tackles Barriers To Use Of Cannabis-Based Medicines in UK

A review of barriers to the prescribing of cannabis-based medicines for children with epilepsy in England suggests that much needs to be done to generate the necessary evidence to assuage prescribers’ concerns. 

United Kingdom Neurology
See All
Advertisement
UsernamePublicRestriction

Register